Docetaxel, cisplatin, and 5-fluorouracil compared with epirubicin,cisplatin, and 5-fluorouracil regimen for advanced gastric cancer:A systematic review and meta-analysis

作     者：Bo Li Lian Chen Hong-Liang Luo Feng-Ming Yi Yi-Ping Wei Wen-Xiong Zhang 

作者机构：Department of Thoracic Surgery The Second Affiliated Hospital of Nanchang University Jiangxi Medical College Nanchang University Department of Gastrointestinal Surgery The Second Affiliated Hospital of Nanchang University Department of Digestive Oncology The Second Affiliated Hospital of Nanchang University 

出 版 物：《World Journal of Clinical Cases》 (世界临床病例杂志)

年 卷 期：2019年第7卷第5期

页      面：600-615页

核心收录：

学科分类：10[医学] 

基　　金：Supported by National Natural Science Foundation of China No.81560345 

主　　题：Gastric cancer Chemotherapy Docetaxel Epirubicin Cisplatin 5-fluorouracil 

摘      要：BACKGROUND As the first-line regimens for the treatment of advanced gastric cancer, both docetaxel, cisplatin, and 5-fluorouracil(DCF) and epirubicin, cisplatin, and 5-fluorouracil(ECF) regimens are commonly used in clinical practice, but there is still controversy about which is *** To compare the efficacy and safety of DCF and ECF regimens by conducting this *** Computer searches in PubMed, EMBASE, Ovid MEDLINE, Science Direct, Web of Science, The Cochrane Library and Scopus were performed to find the clinical studies of all comparisons between DCF and ECF regimens. We used progression-free survival(PFS), overall survival(OS), objective response rate(ORR), disease control rate(DCR), and adverse effects(AEs) as endpoints for *** Our meta-analysis included seven qualified studies involving a total of 598 patients. The pooled hazard ratios between the DCF and ECF groups were comparable in PFS(95%CI: 0.58-1.46, P = 0.73), OS(95%CI: 0.65-1.10, P = 0.21),and total AEs(95%CI: 0.93-1.29, P = 0.30). The DCF group was significantly better than the ECF group in terms of ORR(95%CI: 1.13-1.75, P = 0.002) and DCR(95%CI: 1.03-1.41, P = 0.02). However, the incidence rate of grade 3-4 AEs was also greater in the DCF group than in the ECF group(95%CI: 1.16-1.88, P = 0.002),especially for neutropenia and febrile *** With better ORR and DCR values, the DCF regimen seems to be more suitable for advanced gastric cancer than the ECF regimen. However, the higher rate of AEs in the DCF group still needs to be noticed.